Skip to content
Article Rich – Lifestyle
Author:
Design Therapeutics, Inc.
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
June 30, 2026
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
May 28, 2026
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
May 21, 2026
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
May 21, 2026
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
April 28, 2026
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
March 9, 2026